Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease

1 Jul 2011

Abstract excerpt

OBJECTIVE: To assess the diagnostic potential of imaging striatal monoaminergic terminal integrity with the vesicular monoamine transporter type 2 (VMAT2) radioligand (18)F 9-fluropropyl-(+)-dihydrotetrabenazine ([(18)F]AV-133) and positron emission tomography to distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD). DESIGN, SETTING, AND PARTICIPANTS: Nine patients with DLB, 10 patients with AD,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurotransmitter Receptor Influence on Behavior
Share to Parkinson's Disease Mechanisms and Treatments
Share to Schizophrenia research and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21747030
DOI: 10.1001/archneurol.2011.142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer DiseasePMID 21747030Read ↗

Florzolotau (18F) PET provides in-vivo measures of tau pathology in progressive supranuclear palsy: An imaging-postmortem correlation studySemantic proximity Read ↗

Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography.Semantic proximity Read ↗

Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson’s DiseaseSemantic proximity Read ↗

Altered glutamate signaling in Parkinson’s disease patients with REM sleep behavior disorderSemantic proximity Read ↗

Differential diagnosis of parkinsonian degenerative disorders in combination manual measurements with automated volumetry of the brainSemantic proximity Read ↗

[<sup>18</sup>F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasiaSemantic proximity Read ↗

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.Semantic proximity Read ↗

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.Semantic proximity Read ↗

Characterization of extrastriatal D2 in vivo specific binding of [18F](N‐methyl)benperidol using PETSemantic proximity Read ↗

Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systemsSemantic proximity Read ↗

18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.Semantic proximity Read ↗

Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.